Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined array key "thumbnail" in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 25
StackHealth / Novo Nordisk oral GLP‑1 pill clears FDA for obesity treatment

Novo Nordisk’s Wegovy Pill Becomes First FDA-Approved Oral GLP-1 Drug for Weight Loss

Frank Vinluan / medcitynews - Beyond weight reduction and long-term maintenance of weight loss, the FDA decision for oral Wegovy covers use of the once-daily pill for reducing the risk of major cardiovascular events. Novo Nordisk expects the Wegovy tablet will launch in early January.…

AI Summary: The FDA has given its nod to Novo Nordisk’s oral GLP‑1 receptor agonist for chronic weight management – a historic first for an anti‑obesity pill. The approval offers patients a non‑injectable alternative, potentially transforming obesity care in a market hungry for innovation.

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #drugdevelopment #fda

People who come off slimming jabs regain weight four times faster than dieters

4 months / bbc

Lack of support for people on weight loss drugs leaves them vulnerable to nutritional deficiencies, say experts

4 months / medicalxpress

Poll shows most Americans want to slim down

4 months / medicalxpress

In the UK, 1.6 million adults used weight loss drugs in the past year

4 months / medicalxpress

J.P. Morgan Report: Obesity & Diabetes Dealmaking Set a New Record in 2025

4 months / medcitynews / Frank Vinluan

Weight regain seems to occur within 2 years of stopping obesity drugs

4 months / newscientist

Stopping weight loss drugs linked to weight regain and reversal of heart health markers

4 months / medicalxpress

Ochsner launches program to cut GLP-1 costs

4 months / beckershospitalreview / Ella Jeffries

Ozempic, Wegovy might lower colon cancer risk

4 months / medicalxpress

The GLP-1 Revolution: Medical Aesthetics And The Coming Battle For Control

4 months / medcitynews / Chris Plance

The Weight Loss Market in 2026: 3 Questions That Will Shape the Next Decade

4 months / medcitynews / Shantanu Gaur

MASLD as a complication of obesity must include liver risk stratification

4 months / nature / Mary E. Rinella

Clarification of evidence selection for the framework for the pharmacological treatment of obesity and its complications from the EASO

4 months / nature / Andreea Ciudin

Novo Nordisk launches daily weight-loss pill to expand GLP-1 access

4 months / medicalxpress

Lilly goes back to Nimbus for an oral obesity drug in $55M deal

4 months / endpoints / Kyle LaHucik

Arrowhead’s RNAi obesity programs head to Phase 2 after encouraging early data

4 months / endpoints / Elizabeth Cairns

Older Americans Quit Weight-Loss Drugs in Droves

4 months / kffhealthnews / Paula Span

What is 'oatzempic'? Does it actually work for weight loss?

4 months / medicalxpress

Wegovy pill hits market at $299 per month

4 months / beckershospitalreview / Paige Twenter

GLP-1 drugs might help quell sleep apnea, study suggests

4 months / medicalxpress

Semaglutide may lower burden of hospitalizations in high-risk patients

4 months / medicalxpress

Novo Nordisk launches Wegovy pill at $25 per month for insured patients, $149 cash

4 months / endpoints / Elizabeth Cairns

PHTI: How Employers Can Manage GLP-1 Coverage

4 months / medcitynews / Marissa Plescia

What if Less Can Be More? A New Approach to GLP-1 Weight Loss Medications

4 months / medcitynews / Myra Ahmad

The expanding landscape of GLP-1 medicines

4 months / nature / Daniel J. Drucker

Multi-omic definition of metabolic obesity through adipose tissue–microbiome interactions

4 months / nature / Rima M. Chakaroun

What's ahead for the weight-loss drugs known as GLP-1s in 2026

4 months / npr / Sydney Lupkin

6 recent updates on GLP-1 drugs

5 months / beckershospitalreview / Ella Jeffries

CMS unveils Medicare coverage model for weight loss drugs

5 months / endpoints / Alexis Kramer

Brian Slomovitz: GLP-1 Receptor Agonists Are Changing the World

5 months / oncodaily

Toufic Kachaamy: A Major Shift in Obesity Treatment Just Happened

5 months / oncodaily

CMS launching payment model to boost access to GLP-1s in Medicaid, Part D

5 months / fiercehealthcare

CMS shares GLP-1 model: 7 notes

5 months / beckershospitalreview / Elizabeth Casolo

Novo Nordisk’s Wegovy Pill Becomes First FDA-Approved Oral GLP-1 Drug for Weight Loss

5 months / medcitynews / Frank Vinluan

Novo Nordisk says US approves first GLP-1 pill for weight loss

5 months / medicalxpress

Novo Nordisk eyes a strong launch with FDA approval of obesity pill

5 months / endpoints / Elizabeth Cairns

Back to Top / Tuesday, December 23, 2025, 3:22 pm / permalink 17254 / 36 stories in 5 months /


Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61


Related Stories


Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Novo Nordisk Seeks FDA Nod for Higher‐Dose Wegovy / 6 months

Lilly’s Zepbound bests Novo’s CagriSema in head‑to‑head obesity trial / 3 months

Novo Nordisk commits $2.1B to Vivtex to pursue oral obesity medicines / 2 months

Novo Nordisk legal action threat over copycat Wegovy pill / 3 months

Novo Nordisk GLP‑1 Trials Fail to Check Alzheimer’s Progression / 6 months

GLP‑1 drugs associated with lower addiction risk in large study / 2 months

Lilly fights classification ruling as stockpile and compounding lawsuits swirl / 3 months

StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Clinical Trials, Avian Influenza, Hearing Loss, Public Health and look for the RSS link.


↑

NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.